- Home
- AGEN vs GGR Comparison
AGEN vs GGR Comparison
Compare AGEN & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- GGR
- Stock Information
- Founded
- AGEN 1994
- GGR 2011
- Country
- AGEN United States
- GGR Taiwan
- Employees
- AGEN N/A
- GGR N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GGR Auto Manufacturing
- Sector
- AGEN Health Care
- GGR Consumer Discretionary
- Exchange
- AGEN Nasdaq
- GGR Nasdaq
- Market Cap
- AGEN 87.7M
- GGR 101.1M
- IPO Year
- AGEN 2000
- GGR N/A
- Fundamental
- Price
- AGEN $4.28
- GGR $0.37
- Analyst Decision
- AGEN Buy
- GGR Hold
- Analyst Count
- AGEN 2
- GGR 2
- Target Price
- AGEN $14.50
- GGR $0.50
- AVG Volume (30 Days)
- AGEN 497.3K
- GGR 202.9K
- Earning Date
- AGEN 08-11-2025
- GGR 08-12-2025
- Dividend Yield
- AGEN N/A
- GGR N/A
- EPS Growth
- AGEN N/A
- GGR N/A
- EPS
- AGEN N/A
- GGR N/A
- Revenue
- AGEN $101,706,000.00
- GGR $289,420,000.00
- Revenue This Year
- AGEN $26.25
- GGR N/A
- Revenue Next Year
- AGEN N/A
- GGR $5.00
- P/E Ratio
- AGEN N/A
- GGR N/A
- Revenue Growth
- AGEN N/A
- GGR N/A
- 52 Week Low
- AGEN $1.38
- GGR $0.19
- 52 Week High
- AGEN $7.34
- GGR $1.21
- Technical
- Relative Strength Index (RSI)
- AGEN 38.46
- GGR 53.39
- Support Level
- AGEN $4.31
- GGR $0.36
- Resistance Level
- AGEN $4.70
- GGR $0.38
- Average True Range (ATR)
- AGEN 0.26
- GGR 0.02
- MACD
- AGEN -0.01
- GGR 0.00
- Stochastic Oscillator
- AGEN 17.86
- GGR 66.20
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.